Navigation Links
Abbott’s Laboratories R&D Capabilities Questione

Abbott Laboratories shares fell by 1.3% to close at $43.80 following U.S. Food and Drug Administration (FDA) rejection of its new drug Xinlay. Increased number of scientists and analysts question the efficiency of Abbott’s R&D // , after the rejection of its drug.

The drug that is to be used for the treatment of Prostate cancer failed in its Phase III trial leading to disapproval of the drug by the FDA Panel. Though Abbott is confident of its R&D capabilities and is sure of its other products like Humira, which is used in the treatment of Rheumatoid arthritis and its new drug eluting stent to be approved by the FDA, critics point out that Abbott is not winning in its R&D division as it is doing in Marketing. As FDA as put stringent and tough rules against approval of new drugs following the awful effects of the painkiller drug, Vioxx produced by Merck.

Mike Barr of Victory Capital Management said that, "What's a little disturbing is that Abbott's R&D productivity hasn't been all that great the last few years and looking at the history, they do a very good job at marketing, and it doesn't seem like R&D is up to the same caliber as their marketing." Victory Capital Management owns the shares of Abbott. Another Shareholder of Abbott is The Fifth Third Asset Management, this company is also not happy with Abbott and Mr. Jon Fisher of the company reported that, “It's evident as far as the absolute growth and profitability out of that business and I don't judge by the number of failures, but by the number of successes and how successful they are compared to their pharma peers. They're definitely on the lower end.

Glenn Novarro analyst in Banc of America Securities is optimistic about R&D of Abbott and said that though Xinlay may be a failure its other products in the pipeline like drugs Humira, Simdax, Febuxostat, drug eluting stent and Glucose monitor may succeed. "What is disappointing is that Abbott took a very aggressive approach with t his drug," by filing without a successful Phase III trial, Novarro said. "They clearly made a poor decision." He added, however, that in Abbott's defense, the company isn't a cancer specialist. "They're trying to break into the field, so it's not surprising there would be a stumble along the way."


'"/>




Related medicine news :

1. Dr Reddy’s Laboratories to challenge patents on drug
2. Dr Reddy’s Laboratories launches Hyalosy
3. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
4. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
5. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
6. ICMR to Set up Laboratories to Combat Bird Flu
7. Ranbaxy Laboratories to Be Aided in Drug Research
8. Bangladesh to Set Up HIV/AIDS Diagnosis Laboratories
9. Drug Addicts To Prove ‘Child-Caring Capabilities’ By Clearing Drug Tess
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: